It’s time to take a look at what we can learn from the latest round of talks from the ESMO Breast Cancer conference held late last week.
To be clear this post isn’t a rundown of various company data presentations per se, although a couple are mentioned, but rather it’s a more strategic look at the emergent issues and where we are likely headed in the future.
What trends stand out when we take this approach?
We also segue to ASCO and highlight some relevant key abstracts we’ll be following at the forthcoming meeting.
In short, there’s a lot to think about and accomplish over the next couple of years. As Dr Eric Winer challenged his colleagues – “can we do better?” – and if so, how do we go about achieving this?